January 27, 2023
Coalition for Cannabis Policy, Education, and Regulation Statement on CBD Pathway to Legalization
WASHINGTON, D.C. – Today, the Coalition for Cannabis Policy, Education, and Regulation (CPEAR) released the following statement in response to the Food and Drug Administration’s (FDA) announcement on a regulatory pathway for cannabidiol (CBD).
“The FDA’s announcement is yet another data point reinforcing what we already know – we need a federal regulatory framework for CBD, other hemp-derived cannabinoids, and cannabis-derived cannabinoids that provides clear parameters to address public safety, consumer safety, and youth prevention.
“Right now, the entire country has access to some type of cannabinoid product. Some of the products are intoxicating, and others are not. And with more than 100 million Americans living in a state with legalized, adult-use cannabis, the lack of regulatory clarity means the public doesn’t have the ability to make an informed decision about these products.
“The cannabinoid industry is changing every day. We urge Congress and the FDA to work together to develop a federal framework for all cannabinoids that is grounded in science and responsive to this dynamic and changing marketplace.”
Follow us on Twitter.
###
About the Coalition for Cannabis Policy, Education, and Regulation
A 501(c)(4) non-profit organization, the Coalition for Cannabis Policy, Education, and Regulation (CPEAR) works to advance comprehensive policy solutions for cannabis regulation. The Coalition strives to be a trusted, science-driven resource for lawmakers and the larger stakeholder community, developing responsible policies that protect consumers and patients, prevent underage use, uphold public health and safety, and promote social equity. Comprised of a diverse group of stakeholders, the Coalition brings unique perspectives to the table to thoughtfully address what a federally regulated cannabis industry should look like. To learn more, visit www.CPEAR.org and follow us on Twitter.